3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoro-2-(fluoromethyl)propyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol

ID: ALA4871601

Chembl Id: CHEMBL4871601

PubChem CID: 164621192

Max Phase: Preclinical

Molecular Formula: C28H32F6N4O

Molecular Weight: 554.58

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CC(CF)CF)C3)cc2F)N1CC(F)(F)CO

Standard InChI:  InChI=1S/C28H32F6N4O/c1-16-6-21-20-4-2-3-5-24(20)36-26(21)27(38(16)14-28(33,34)15-39)25-22(31)7-18(8-23(25)32)35-19-12-37(13-19)11-17(9-29)10-30/h2-5,7-8,16-17,19,27,35-36,39H,6,9-15H2,1H3/t16-,27-/m1/s1

Standard InChI Key:  OPWXYDBEXHCDKA-CHAGWJKLSA-N

Alternative Forms

1. Parent:

   

   ALA4871601

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 554.58

Molecular Weight (Monoisotopic): 554.2480

AlogP: 5.06

#Rotatable Bonds: 10

Polar Surface Area: 54.53

Molecular Species: NEUTRAL

HBA: 4

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.81

CX Basic pKa: 7.17

CX LogP: 4.31

CX LogD: 4.10

Aromatic Rings: 3

Heavy Atoms: 39

QED Weighted: 0.31

Np Likeness Score: -0.40

References

1. Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, Friedman LS, Gelzleichter T, Gill M, Giltnane JM, Goodacre S, Guan J, Hartman SJ, Ingalla ER, Kategaya L, Kiefer JR, Kleinheinz T, Labadie SS, Lai T, Li J, Liao J, Liu Z, Mody V, McLean N, Metcalfe C, Nannini MA, Oeh J, O'Rourke MG, Ortwine DF, Ran Y, Ray NC, Roussel F, Sambrone A, Sampath D, Schutt LK, Vinogradova M, Wai J, Wang T, Wertz IE, White JR, Yeap SK, Young A, Zhang B, Zheng X, Zhou W, Zhong Y, Wang X..  (2021)  GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,  64  (16.0): [PMID:34251202] [10.1021/acs.jmedchem.1c00847]

Source

Source(1):

• Scientific Literature